Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

The H1-antagonist mequitazine: studies on performance and visual function.

A N Nicholson, B M Stone

    European Journal of Clinical Pharmacology
    |January 1, 1983
    PubMed
    Summary
    This summary is machine-generated.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Phenobarbital toxicosis in a pied butcherbird, Cracticus nigrogularis.

    Australian veterinary journal·2025
    Same author

    A per-cent-level determination of the nucleon axial coupling from quantum chromodynamics.

    Nature·2018
    Same author

    Duration of activity and mode of action of modafinil: Studies on sleep and wakefulness in humans.

    Journal of psychopharmacology (Oxford, England)·2013
    Same author

    Indigofera spicata (creeping indigo) poisoning of three ponies.

    Australian veterinary journal·2013
    Same author

    Human performance after a barbiturate (heptabarbitone).

    British journal of clinical pharmacology·2012
    Same author

    Performance and impaired performance.

    British journal of clinical pharmacology·2012

    Mequitazine and terfenadine, H1 antagonists, were evaluated for side effects. Mequitazine (10 mg) showed some impairment, while terfenadine had no significant effects, suggesting they may be suitable when sedation is a concern.

    Area of Science:

    • Pharmacology
    • Neuroscience
    • Clinical Trials

    Background:

    • First-generation antihistamines often cause sedation and cognitive impairment.
    • Development of non-sedating H1 antagonists is crucial for improving patient compliance and safety.

    Purpose of the Study:

    • To evaluate the effects of mequitazine and terfenadine on cognitive and psychomotor performance.
    • To compare the safety profile of mequitazine and terfenadine against active controls and placebo.

    Main Methods:

    • Double-blind, placebo-controlled study involving six healthy female volunteers.
    • Assessment of visuo-motor coordination, digit symbol substitution, critical flicker fusion, and dynamic visual acuity.
    • Subjective assessments of mood and well-being were also recorded.

    Related Experiment Videos

    Main Results:

    • Mequitazine (10 mg) impaired visuo-motor coordination and digit symbol substitution.
    • Terfenadine (60 mg) demonstrated no significant effects on cognitive or psychomotor performance.
    • Triprolidine (10 mg) significantly impaired multiple cognitive and psychomotor functions.

    Conclusions:

    • Mequitazine (5 mg) and terfenadine (60 mg) appear to be acceptable H1 antagonists with minimal sedative effects.
    • These findings support the use of mequitazine and terfenadine in situations where avoiding sedation is important.